目的探讨KI-67、P53、BCL-2与子宫平滑肌肿瘤的关系及其临床意义。方法采用免疫组化方法检测38例子宫平滑肌瘤、36例具恶性潜能的平滑肌瘤(STUMP)和33例子宫平滑肌肉瘤中KI-67、P53、BCL-2的表达。结果①KI-67、P53在子宫肉瘤中的表达强于子宫平滑肌瘤。②BCL-2在子宫肉瘤中的表达弱于子宫平滑肌瘤。结论LMS患者BCL-2表达越强,其生存期越长。K I-67、P53、BCL-2有可能成为区别子宫平滑肌肉瘤与子宫平滑肌瘤及判断子宫平滑肌肉瘤预后的指标。 Objective To investigate the relationship between KI-67, P53, BCL-2 and uterine smooth muscle tumors and their clinical significance. Methods Immunohistochemistry was used to detect the expression of KI-67, P53 and BCL-2 in 38 cases of uterine leiomyoma, 36 cases of malignant potential leiomyoma (STUMP) and 33 cases of uterine leiomyosarcoma. Results ① The expression of KI-67 and P53 in uterine sarcoma was stronger than that in uterine leiomyomas. ②BCL-2 expression in uterine sarcoma is weaker than uterine leiomyoma. Conclusion The stronger the expression of BCL-2 in LMS patients, the longer its survival. K I-67, P53, BCL-2 may be the difference between uterine leiomyosarcoma and uterine leiomyoma and to determine the prognosis of uterine leiomyosarcoma.